Member Info for stt1

also from Interims - Revenues from consumer, ex petcare, was £35k for the full 6 months.
(£410k consumer including petcare.)

Even a 10 fold increase in consumer sales, ex petcare, will only be £350k for a full 6 months.

I'm sure Byot will get a spike in sales like they did post Swine Flu but how much is already in the price.

"Headline H1 revenues in this segment were £0.41m versus £0.45m in H1 2018 (as restated). Petcare remains the largest element of day-to-day sales in consumer, accounting for 92% of consumer sales in the period. "

Frac,
"supplying the current customer base . "

Boots is their customer and are still out of stock. It makes more sense to supply Boots with their millions of customers, than to sell 30x50ml bottles direct to individual customers.

Regarding buying 30x50ml bottles - 50ml sanitiser typically has 100 applications, even if using twice a day, that's 50 days with 1 50ml bottle. 30 bottles is 1500 days or 4yrs worth.

Frac
"30 invirtu 50 ml foam hand sanitisers for £75"

£2.50 for a 50ml bottle!! That's very expensive. Why would anyone need 30x50ml bottles ?

Budget on Wed. Chancellor's comments on Covid-19

Coronavirus: NHS will get whatever it needs, says chancellor

He said: "I can say absolutely, categorically, the NHS will get whatever resources it needs to get us through this crisis."

https://www.bbc.co.uk/news/uk-51790242

Yazo,

"They will not have it these perfect conditions in a while. "

Agree, it's a great window of opportunity which Byot seem to be missing.
5 weeks now and Byot still sold out on Boots site, still a trial at Target.
Selling on Amazon is ok but it's tiny sells compared to the opportunity via Boots.

Also majority of people are likely to buy healthcare products from known and trusted retailers and online sellers.

SLF
" Could you try adding a little humour please."

ok. Just for you...

The initial patent was around 25yrs ago. Byot IPO was around 15yrs ago.

Humour:
Are their products or their partnerships longer lasting???
lol

Hooterr,
"This company has the best defence against Coviid-19 for long duration sanitising of hands and hard surfaces. "

The initial patent was around 25yrs ago. Byot IPO was around 15yrs ago.

Yet why during those 15yrs of being listed, why haven't larger companies been scrambling to buy them, why aren't IIs buying in large quantities?

Tardigrades,
"Popular 50mlpocket size"
?
Still says 'stock coming soon'.

Ian,

" Hopefully we are in talks with potential big players with lots of interest in our type of products."

The outbreak may have months to run but they have been seeking a partner for months.

It takes time to agree terms of a partnership and then to supply.
By that time people and businesses will have sourced and stocked their supplies.

Missed opportunity?

"Financial Resources
At the year-end we had cash resources of £2.8m (2018: £3.85m) which is sufficient to finance our ongoing operations and the remaining earnout payments to Medimark’s vendors but not to fund additional resources, capabilities and nationwide marketing expenditure in the US."

https://byotrolplc.com/wp-content/uploads/2019/10/Byotrol-Annual-Report-FY-2018-19.pdf

They've been seeking a partner in US for months.
Byot at Target stores is a trial due to end this month, despite it being announced over 18 months ago.

Byot should get a spike in sales due to increased sales but a big window of opportunity lost.

It's a fact, that 666k trade is a sell from yesterday, reported today.

Check the date and time of the trade.

Tip,
"Large sells maybe, but large buys too."

The sells over the last 2 days far outweigh the smaller buys.

Where are these

Some large sells being reported today.

Over 4 weeks now, Byot based hand sanitiser sold out at Boots.

https://www.boots.com/boots-anti-viral-hand-foam%E2%80%93200-ml-10231389

Tricky,

"How on earth could their holdings arrest the changing evolution in the industry?"

I never said their holding would.
I posted "Didn't they see the challenges when, in 2017, the world's largest advertiser, P&G, issued warnings to Ad Tech to clean up it's act?"

The point is Tosca holding rns in Jan 2017 shows they had 29%. During the SAME month, P&G, issued warnings to Ad Tech to clean up it's act. Didn't they see the consequences of such a statement on ad tech by the largest advertisers. It's obvious if the largest customer in the world demands changes then the industry has to heed the warnings or companies will suffer the consequences.
Given part of those P&G demands included 'fee transparency', why would rthm then shot themselves in the foot, just a few months later by taking action against DataXu?

Rubicon on the other hand mutually resolved their 'fees' issues with The Guardian and it was publised. Have you noticed how well Rubicon have done since compared to rthm?

Therefore, Tosca's holding makes no difference to the company's prospects.

High quality D color as well..

https://www.gemdiamonds.com/

Tricky,
"Clearly they see potential whilst the markets present an opportunity."

Tosca had been buying and holding rthm for several years and buying at significantly higher prices.

They held 29% of Rthm 3 yrs ago. Their clearly got the potential wrong. Their holding didn't stop the well documented Industry Challenges. Didn't they see the challenges when, in 2017, the world's largest advertiser, P&G, issued warnings to Ad Tech to clean up it's act?
https://adage.com/article/media/p-g-s-pritchard-calls-digital-grow-up-new-rules/307742

If their holding hasn't made a difference for several years then why should it make a difference this time?

Tosca Holding rns from Jan 2017 - 29%

https://investegate.co.uk/rhythmone-plc--rthm-/rns/holding-s--in-company/201701051449544743T/

"No1 recommendation from the government in tackling COVID-19 is watching your hands regularly"

That has been WHO/CDC/NHS advice for years, it's not new...

Wiki has a long article on Matomy. Also mentions Ofer and Sagi Niri. Interesting read.

https://en.wikipedia.org/wiki/Matomy_Media